Skip to content

The verification study for safety evaluation of excessive the test food ingestion in humans: a randomized, double-blind, placebo-controlled, parallel study

The verification study for safety evaluation of excessive the test food ingestion in humans: a randomized, double-blind, placebo-controlled, parallel study - The verification study for safety evaluation of excessive the test food ingestion in humans

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000031218
Enrollment
40
Registered
2018-02-09
Start date
2018-02-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Japanese adult people

Interventions

Duration: 4 weeks Test materials: Tablets containing Bacillus subtilis Dose: 18 tablets per day Administration: Take the test tablets with water multiple times per day. Do not chew tablets. * Dail

Sponsors

ORTHOMEDICO Inc.
Lead Sponsor
Medical Corporation Seishinkai, Takara Clinic
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Healthy Japanese adult people 2. Subjects who are judged as eligible to participate in the study by the physician

Exclusion criteria

Exclusion criteria: 1. A medical history of malignant tumor, heart failure or myocardial infarction 2. Currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, irritable bowel syndrome, osteoporosis, or any other chronic diseases 3. Subjects who daily consume "Foods for Specified Health Uses" or "Foods with Functional Claims" 4. Currently taking medications (include herbal medicines) and supplements *Particularly taking warfarin 5. Subjects who are allergic to medications and/or products related to the study substance *Particularly soybeans, natto allergy 6. Subjects who have lactose intolerance 7. Subjects who are pregnant, lactation, and planning to become pregnant 8. Subjects who have been enrolled in other clinical trials within the last three months before the agreement to participate in this trial 9. Subjects who are judged as ineligible to participate in the study by the physician

Design outcomes

Primary

MeasureTime frame
1. Physical examination 2. Urinalysis 3. Blood test *1-3 Perform the test at screening and examination before consuming and at 2, and 4 weeks after ingestion

Secondary

MeasureTime frame
Simple measurement of bone mineral density *Perform the test at screening and examination before consuming and at 2, and 4 weeks after ingestion

Countries

Japan

Contacts

Public ContactNaoko SUZUKI

ORTHOMEDICO Inc. R&D Department

nao@orthomedico.jp03-3818-0610

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026